Journey Medical Corporation
General ticker "DERM" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $186.7M (TTM average)
Journey Medical Corporation does not follow the US Stock Market performance with the rate: -0.1%.
Estimated limits based on current volatility of 3.6%: low 5.01$, high 5.38$
Factors to consider:
- Total employees count: 58 (+41.5%) as of 2025
- Top business risk factors: Going concern doubt, Inability to raise capital, Regulatory and compliance, Third-party risks, Clinical trial delays
- Current price 12.9% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.71$, 10.93$]
- 2026-12-31 to 2027-12-31 estimated range: [5.64$, 10.82$]
Financial Metrics affecting the DERM estimates:
- Positive: with PPE of -16.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: -13.52 < Operating profit margin, % of -11.67
- Positive: -51.61 < Industry operating profit margin (median), % of -17.91
- Negative: 25.20 < Shareholder equity ratio, % of 33.67 <= 34.41
- Negative: Investing cash flow per share per price, % of 0 <= 2.08
Short-term DERM quotes
Long-term DERM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $79.18MM | $56.13MM | $61.86MM |
| Operating Expenses | $81.25MM | $69.81MM | $70.03MM |
| Operating Income | $-2.07MM | $-13.68MM | $-8.17MM |
| Non-Operating Income | $-1.56MM | $-0.93MM | $-3.20MM |
| Interest Expense | $1.70MM | $2.70MM | $3.70MM |
| R&D Expense | $7.54MM | $9.86MM | $0.48MM |
| Income(Loss) | $-3.63MM | $-14.61MM | $-11.37MM |
| Taxes | $0.22MM | $0.06MM | $0.06MM |
| Net Income(Loss)* | $-3.85MM | $-14.67MM | $-11.43MM |
| Stockholders Equity | $20.35MM | $20.07MM | $31.85MM |
| Inventory | $10.21MM | $14.43MM | $9.62MM |
| Assets | $76.85MM | $80.24MM | $94.59MM |
| Operating Cash Flow | $5.24MM | $-9.13MM | $-12.44MM |
| Capital expenditure | $5.00MM | $15.00MM | $0.00MM |
| Investing Cash Flow | $-5.00MM | $-15.00MM | $0.00MM |
| Financing Cash Flow | $-4.80MM | $16.99MM | $16.23MM |
| Earnings Per Share** | $-0.21 | $-0.72 | $-0.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.